| Basics |
Spero Therapeutics, Inc.
Spero Therapeutics Inc is a multi asset clinical stage biopharmaceutical company. It is focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections.
|
| IPO Date: |
November 2, 2017 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$38.13M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.25 | 3.10%
|
| Avg Daily Range (30 D): |
$0.03 | 2.84%
|
| Avg Daily Range (90 D): |
$0.03 | 3.32%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.49M |
| Avg Daily Volume (30 D): |
4.71M |
| Avg Daily Volume (90 D): |
1.66M |
| Trade Size |
| Avg Trade Size (Sh.): |
246 |
| Avg Trade Size (Sh.) (30 D): |
276 |
| Avg Trade Size (Sh.) (90 D): |
283 |
| Institutional Trades |
| Total Inst.Trades: |
89 |
| Avg Inst. Trade: |
$1.76M |
| Avg Inst. Trade (30 D): |
$.59M |
| Avg Inst. Trade (90 D): |
$.59M |
| Avg Inst. Trade Volume: |
.18M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.1M |
| Avg Closing Trade (30 D): |
$M |
| Avg Closing Trade (90 D): |
$M |
| Avg Closing Volume: |
298.25K |
|
|
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q4 2024 |
|
Basic EPS
|
$-1.28
|
$-.25
|
$-.38
|
|
Diluted EPS
|
$-1.28
|
$-.25
|
$-.38
|
|
Revenue
|
$ 44.58M
|
$ 5.87M
|
$ 15.04M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -69.76M
|
$ -13.87M
|
$ -20.89M
|
|
Operating Income / Loss
|
$ -74.11M
|
$ -14.73M
|
$ -21.73M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -33.38M
|
$ -4M
|
$ -23.4M
|
|
PE Ratio
|
|
|
|
|
